Skip Navigation LinksHome > February 2014 - Volume 259 - Issue 2 > Nationwide Study of 4741 Patients With Non-B Non-C Hepatocel...
Annals of Surgery:
doi: 10.1097/SLA.0b013e31829291e9
Original Articles

Nationwide Study of 4741 Patients With Non-B Non-C Hepatocellular Carcinoma With Special Reference to the Therapeutic Impact

Utsunomiya, Tohru MD, PhD*; Shimada, Mitsuo MD, PhD*; Kudo, Masatoshi MD, PhD; Ichida, Takafumi MD, PhD; Matsui, Osamu MD, PhD§; Izumi, Namiki MD, PhD; Matsuyama, Yutaka MD, PhD; Sakamoto, Michiie MD, PhD**; Nakashima, Osamu MD, PhD††; Ku, Yonson MD, PhD‡‡; Kokudo, Norihiro MD, PhD§§; Makuuchi, Masatoshi MD, PhD; Liver Cancer Study Group of Japan¶¶; Liver Cancer Study Group of Japan

Supplemental Author Material
Collapse Box

Abstract

Objective: To examine the prognostic factors and outcomes after several types of treatments in patients with hepatocellular carcinoma (HCC) negative for hepatitis B surface antigen and hepatitis C antibody, so-called “non-B non-C HCC” using the data of a nationwide survey.

Background: The proportion of non-B non-C HCC is rapidly increasing in Japan.

Methods: A total of 4741 patients with non-B non-C HCC, who underwent hepatic resection (HR, n = 2872), radiofrequency ablation (RFA, n = 432), and transcatheter arterial chemoembolization (TACE, n = 1437) as the initial treatment, were enrolled in this study. The exclusion criteria included extrahepatic metastases and/or Child-Pugh C. Significant prognostic variables determined by a univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model.

Results: The degree of liver damage in the HR group was significantly lower than that in the RFA and TACE groups. The HR and TACE groups had significantly more advanced HCC than the RFA group. The 5-year survival rates after HR, RFA, and TACE were 66%, 49%, and 32%, respectively. Stratifying the survival rates, according to the TNM stage and the Japan Integrated Staging (JIS) score, showed the HR group to have a significantly better prognosis than the RFA group in the stage II and in the JIS scores “1” and “2.” The multivariate analysis showed 12 independent prognostic factors. HR offers significant prognostic advantages over TACE and RFA.

Conclusions: The findings of this large prospective cohort study indicated that HR may be recommended, especially in patients with TNM stage II and JIS scores “1” and “2” of non-B non-C HCC.

© 2014 by Lippincott Williams & Wilkins.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.